What is Nektar Therapeutics's market cap?

Nektar Therapeutics (NKTR) has a market capitalization of $2.4B and trades on NASDAQ.

What is Nektar Therapeutics's revenue and profitability?

Nektar Therapeutics generated $55.6M in trailing twelve-month revenue with a net loss of $158.1M, representing a net margin of -284.2%. Gross margin stands at 100.0%, with free cash flow of -$203.9M. These figures are based on the Q1 2026 filing.

Who are Nektar Therapeutics's competitors?

Nektar Therapeutics's key competitors include ImmunityBio, Inc., Nkarta, Inc., Regeneron, and others. These companies compete in similar markets and product categories.

Who does Nektar Therapeutics partner with?

Nektar Therapeutics's notable partners include Eli Lilly and Company, TrialNet, Merck KGaA, and others.

What subsidiaries does Nektar Therapeutics have?

Nektar Therapeutics's subsidiaries include Gannet BioChem.

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in United States of America and employs approximately 137 people. It has been publicly traded since 1994.

Nektar Therapeutics

NKTR

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunomodulatory agents.

Market cap

$2.41B+531%

Revenue$55.6M-36.2%

Net income-$158.1M-12.7%

Free cash flow-$203.9M-14.5%

EPS (diluted)-$8.23+32.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$10.9MBeat by $169.6K EPS-$1.82Miss by $0.08

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$10.4M

EPS estimate-$1.94

Financials

Q1 2026

Income statement

See full

Revenue$10.9M+3.8%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation & ratios

Valuation

See full

Market cap$2.41B+531%

Enterprise value$2.49B+399%

P/S43.3×+37.9×

Profitability

See full

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Segments

By product

See full

Non Cash Royalty Revenue Related To Sale Of Future Royalties$10.9M+3.8%

Competitors

By market cap

Amgen$203.07B+25.3%

Regeneron Pharmaceuticals$69.9B+16.0%

Apogee Therapeutics, Inc.$10.2B+339%

ImmunityBio, Inc.$7.3B+213%

Nektar Therapeutics$2.4B+489%

Artiva Biotherapeutics, Inc.$501.4M+595%

Nkarta, Inc.$161.7M+3.6%

Kairos Pharma$6.6M-54.9%

By revenue growth

ImmunityBio, Inc.+352%

Amgen+9.1%

Regeneron Pharmaceuticals+5.9%

Nektar Therapeutics-36.2%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Amgen20.96%+3.6pp

Artiva Biotherapeutics, Inc.-79.28%—

Nektar Therapeutics-284.18%-123pp

ImmunityBio, Inc.-606.15%+704pp

Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunomodulatory agents. The company leverages its deep understanding of immunology and advanced polymer conjugate technology to create drug candidates that selectively induce, amplify, or attenuate immune responses. Its primary value proposition lies in rebalancing the immune system to treat autoimmune diseases and activating natural tumor-fighting mechanisms to treat cancer.

Competitive position

Nektar is a leader in polymer conjugate technology (PEGylation) with a diverse pipeline of first-in-class immunomodulatory candidates in clinical development.

GeographiesUnited States, Europe

Customer segmentsPharmaceutical companies, Clinical research organizations, Healthcare systems

Business modelR&D-based drug discovery, Licensing and Royalties, Strategic Collaborations

SuppliersContract Manufacturing Organizations (CMOs), Specialized chemical suppliers, Gannet BioChem (PEG reagent supply)

CustomersGlobal pharmaceutical partners, Clinical trial participants, Specialty pharmacies, Hospitals and clinics

CountryUnited States of America

Listed1994

Employees137.0

CEOHoward W. Robin

SectorHealthcare

IndustryBiotechnology

Websitenektar.com

FilingsSEC EDGAR

Ask your AI about Nektar Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's market cap?: Nektar Therapeutics (NKTR) has a market capitalization of $2.4B and trades on NASDAQ.
What is Nektar Therapeutics's revenue and profitability?: Nektar Therapeutics generated $55.6M in trailing twelve-month revenue with a net loss of $158.1M, representing a net margin of -284.2%. Gross margin stands at 100.0%, with free cash flow of -$203.9M. These figures are based on the Q1 2026 filing.
Who are Nektar Therapeutics's competitors?: Nektar Therapeutics's key competitors include ImmunityBio, Inc., Nkarta, Inc., Regeneron, and others. These companies compete in similar markets and product categories.
Who does Nektar Therapeutics partner with?: Nektar Therapeutics's notable partners include Eli Lilly and Company, TrialNet, Merck KGaA, and others.
What subsidiaries does Nektar Therapeutics have?: Nektar Therapeutics's subsidiaries include Gannet BioChem.
Where is Nektar Therapeutics headquartered?: Nektar Therapeutics is headquartered in United States of America and employs approximately 137 people. It has been publicly traded since 1994.